Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson’s disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex’s GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABAB PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson’s disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN".
Company Details
- Employees
- 22
- Founded
- -
- Address
- Chemin Des Aulx 12, Case Postale 68,switzerland
- Phone
- 41228841555
- in****@****ics.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- addextherapeutics.com
- Keywords
- allosteric modulation, Parkinson's disease, schizophrenia, inflammation, metabolic, diabetes, dyskinesia, anxiety, pain, depression, PTSD, Alzheimer's, mGlu, mGluR, GABA, FSH, GLP-1, TNF, IL-1.
- HQ
- Plan-Les-Ouates, Switzerland
Addex Therapeutics Questions
Addex Therapeutics's helpline number is 41228841555
Addex Therapeutics's website is addextherapeutics.com
Addex Therapeutics's LinkedIn profile is https://ch.linkedin.com/company/addex-therapeutics
Addex Therapeutics has
22 employees.
View email and phone details for 22
employees at Addex Therapeutics.
Addex Therapeutics's industry is
Biotechnology Research
Addex Therapeutics's top competitors are
Ac Immune,
Neurosterix,
Gliapharm Sa,
Debiopharm,
Light Chain Bioscience | Novimmune Sa,
Amal Therapeutics,
Ionctura,
Geneuro Sa,
Adc Therapeutics,
Alentis Therapeutics.
Addex Therapeutics's support email address is info@addextherapeutics.com
Addex Therapeutics's categories are Biotechnology Research
Addex Therapeutics's founding year is 2002
